A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer.

Biotherapy (Dordrecht, Netherlands) Pub Date : 1996-01-01 DOI:10.1007/BF02628669

G Pizza, C De Vinci, D Cuzzocrea, D Menniti, E Aiello, P Maver, G Corrado, P Romagnoli, E Dragoni, G LoConte, U Riolo, A Palareti, P Zucchelli, V Fornarola, D Viza

{"title":"A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer.","authors":"G Pizza, C De Vinci, D Cuzzocrea, D Menniti, E Aiello, P Maver, G Corrado, P Romagnoli, E Dragoni, G LoConte, U Riolo, A Palareti, P Zucchelli, V Fornarola, D Viza","doi":"10.1007/BF02628669","DOIUrl":null,"url":null,"abstract":"<p><p>As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able to transfer, in vitro and in vivo, CMI against bladder and prostate TAA. Fifty patients entered this study and received one intramuscular injection of 2-5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage.</p>","PeriodicalId":77043,"journal":{"name":"Biotherapy (Dordrecht, Netherlands)","volume":"9 1-3","pages":"123-32"},"PeriodicalIF":0.0000,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02628669","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotherapy (Dordrecht, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02628669","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 21

Abstract

As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able to transfer, in vitro and in vivo, CMI against bladder and prostate TAA. Fifty patients entered this study and received one intramuscular injection of 2-5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage.

查看原文本刊更多论文

转移因子用于治疗D3期激素无反应性转移性前列腺癌的初步报道。

由于常规治疗不成功，D3期前列腺癌患者的生存率很低。有报道表明存在针对前列腺癌肿瘤相关抗原(TAA)的体液和细胞介导免疫(CMI)。这些观察结果促使我们使用体外产生的转移因子(TF)治疗D3期前列腺癌患者，该转移因子能够在体外和体内转移CMI对抗膀胱和前列腺TAA。50例患者进入这项研究，每月接受一次肌肉注射2-5单位的特异性TF。随访时间从1年到9年不等，结果显示2例患者完全缓解，6例患者部分缓解，14例患者无转移进展。中位生存期为126周，高于文献报道的同阶段患者的生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotherapy (Dordrecht, Netherlands)

自引率

0.00%

发文量